Nautilus Biotechnology Other Assets Over Time

NAUT Stock  USD 2.24  0.20  8.20%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Nautilus Biotechnology Performance and Nautilus Biotechnology Correlation.
For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.
  
Other Assets is likely to gain to about 1.3 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nautilus Biotechnology. If investors know Nautilus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nautilus Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Return On Assets
(0.18)
Return On Equity
(0.28)
The market value of Nautilus Biotechnology is measured differently than its book value, which is the value of Nautilus that is recorded on the company's balance sheet. Investors also form their own opinion of Nautilus Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Nautilus Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nautilus Biotechnology's market value can be influenced by many factors that don't directly affect Nautilus Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nautilus Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nautilus Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nautilus Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Other Assets Analysis

Compare Nautilus Biotechnology and related stocks such as C4 Therapeutics, Kymera Therapeutics, and Foghorn Therapeutics Other Assets Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CCCC2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M2.6 M3.8 M4.8 M5.5 M3.6 M
KYMR199 K199 K199 K199 K199 K199 K199 K199 K199 K1.8 M1.6 M8.1 M9.1 M10.5 M11 M
FHTX566 K566 K566 K566 K566 K566 K566 K566 K566 K1.7 M2.6 M4.1 M4.1 M1.00.95
RVMD383 K383 K383 K383 K383 K383 K383 K383 K593 K2.8 M1.4 M2.5 M4.6 M1.00.95
IPSC4.4 M4.4 M4.4 M4.4 M4.4 M4.4 M12.1 M206 K206 K206 K2.1 M3.5 M3.2 M1.00.95
BCAB97 K97 K97 K97 K97 K97 K97 K97 K97 K154 K154 K154 K0.01.00.95
PMVP201 K201 K201 K201 K201 K201 K201 K201 K201 K201 K201 K221 K313 K1.00.95
CRBU593 K593 K593 K593 K593 K593 K593 K593 K593 K593 K612 K975 K1.5 M1.8 MM
DTIL187 K187 K187 K187 K187 K187 K187 K124 K312 K558 K8.1 M11.5 M9.8 M1.00.95
BEAM1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M18.3 M18 M14.5 M14.7 M16.9 M14.8 M
MNOV8.4 M0.00.00.011 K109 K0.011 K11 K59.8 KM97.9 M92.8 K106.7 K101.4 K
MOLN5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M5.1 M4.6 MM
CSBR11 K150 K1000165 K163 K150 K257 K266 K128 K128 K15 K15 K15 K17.2 K16.4 K
ANEB(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)(1 M)422.7 K422.7 K486.2 K510.5 K
RZLT750 K750 K750 K750 K563 K375 K330.6 K90 K35 K31 K191 K0.0148 K1.00.95
HCWB34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K34.2 K393.3 K333.9 K384 K218.8 K

Nautilus Biotechnology and related stocks such as C4 Therapeutics, Kymera Therapeutics, and Foghorn Therapeutics Other Assets description

My Equities

My Current Equities and Potential Positions

Nautilus Biotechnology
NAUT
ClassificationMeasuring and Control Equipment
LocationWashington; U.S.A
ExchangeNASDAQ Exchange
USD 2.24

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.